Table 1_Associations between systemic immune-inflammation index and immune-related hypothy

Wei Dai's retrospective study includes data from 160 driver gene-negative non-small cell lung cancer patients who received first-line PD-1 inhibitor therapy combined with chemotherapy. The dataset likely contains baseline clinical and laboratory variables used to investigate the association between the systemic immune-inflammation index and immune-related hypothyroidism. The study was conducted at Yancheng Third People’s Hospital between October 2019 and December 2024.

Use Cases

• Developing a predictive nomogram for immune-related hypothyroidism based on baseline SII and other clinical factors.
• Analyzing the relationship between systemic immune-inflammatory status and endocrine adverse events in NSCLC patients.
• Validating the discriminative ability of a clinical prediction model using ROC curve analysis.
• Conducting subgroup analysis to compare SII levels between patients with and without hypothyroidism across different NSCLC subtypes.

Strengths

• Includes 160 patient records with a defined outcome group split (65 irH, 95 non-irH).
• Multivariate analysis identified specific independent predictors (log2-SII, age, TG, LDL, TB, FIB, D-dimer).
• The developed nomogram achieved an AUC of 0.884, indicating potential discriminative ability.

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• Data is from a single hospital (Yancheng Third People’s Hospital), which may limit generalizability.
• The dataset is very small at 13.1 KB, indicating limited scope.

Provenance

Source

Yancheng Third People’s Hospital (inferred from description).

Collection Method

Retrospective study of patient records.

Time Range

October 2019 to December 2024.

Freshness

Last updated 2026-06-02 04:28:25; freshness should be verified.

Geography

Likely China (based on hospital location).